Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?

dc.contributor.author

Orlowsky, Eric W

dc.contributor.author

Stabler, Thomas V

dc.contributor.author

Montell, Eulàlia

dc.contributor.author

Vergés, Josep

dc.contributor.author

Kraus, Virginia Byers

dc.date.accessioned

2019-02-02T15:32:40Z

dc.date.available

2019-02-02T15:32:40Z

dc.date.issued

2014-09-27

dc.date.updated

2019-02-02T15:32:39Z

dc.description.abstract

Chondroitin Sulphate (CS), a natural glycosaminoglycan of the extracellular matrix, has clinical benefit in symptomatic osteoarthritis but has never been tested in gout. In vitro, CS has anti-inflammatory and positive effects on osteoarthritic chondrocytes, synoviocytes and subchondral bone osteoblasts, but its effect on macrophages is unknown. The purpose of our study was to evaluate the in vitro effects of CS on monosodium urate (MSU)-stimulated cytokine production by macrophages.THP-1 monocytes were differentiated into mature macrophages using a phorbol ester, pretreated for 4 hours with CS in a physiologically achievable range of concentrations (10-200 μg/ml) followed by MSU crystal stimulation for 24 hours. Cell culture media were analyzed by immunoassay for factors known to be upregulated during gouty inflammation including IL-1β, IL-8 and TNFα. The specificity of inflammasome activation by MSU crystals was tested with a caspase-1 inhibitor (0.01 μM-10 μM).MSU crystals ≥10 mg/dl increased macrophage production of IL-1β, IL-8 and TNFα a mean 7-, 3- and 4-fold respectively. Induction of IL-1β by MSU was fully inhibited by a caspase-1 inhibitor confirming inflammasome activation as the mechanism for generating this cytokine. In a dose-dependent manner, CS significantly inhibited IL-1β (p = 0.003), and TNFα (p = 0.02) production from macrophages in response to MSU. A similar trend was observed for IL-8 but was not statistically significant (p = 0.41).CS attenuated MSU crystal induced macrophage inflammation, suggesting a possible role for CS in gout prophylaxis.

dc.identifier

1471-2474-15-318

dc.identifier.issn

1471-2474

dc.identifier.issn

1471-2474

dc.identifier.uri

https://hdl.handle.net/10161/18053

dc.language

eng

dc.publisher

Springer Science and Business Media LLC

dc.relation.ispartof

BMC musculoskeletal disorders

dc.relation.isversionof

10.1186/1471-2474-15-318

dc.subject

Monocytes

dc.subject

Cell Line

dc.subject

Macrophages

dc.subject

Humans

dc.subject

Gout

dc.subject

Inflammation

dc.subject

Uric Acid

dc.subject

Chondroitin Sulfates

dc.subject

Drug Evaluation, Preclinical

dc.subject

Dose-Response Relationship, Drug

dc.title

Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?

dc.type

Journal article

duke.contributor.orcid

Kraus, Virginia Byers|0000-0001-8173-8258

pubs.begin-page

318

pubs.issue

1

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Duke Molecular Physiology Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Orthopaedics

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Pathology

pubs.organisational-group

Medicine, Rheumatology and Immunology

pubs.organisational-group

Medicine

pubs.publication-status

Published

pubs.volume

15

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?.pdf
Size:
656.79 KB
Format:
Adobe Portable Document Format